Key result
Platelet-rich plasma needs preclinical mechanistic research to improve potency and overcome variable clinical outcomes.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tomoyuki Kawase (2022) conducted an editorial in Tissue regeneration. Platelet-rich plasma (PRP) and Platelet-rich fibrin (PRF) was evaluated. Platelet-rich plasma research should focus on basic and pre-clinical aspects to clarify mechanisms, enhance potency, and prolong action to overcome individual differences in clinical outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: